New Sickle Cell Medication Adakveo To Reduce Pain Crises

| January 19, 2020 @ 6:00 pm

By Savannah Koplon

For individuals living with sickle cell disease, vaso-occlusive crises are acute painful events that cause severe morbidity and decrease one’s quality of life.

Vaso-occlusive crises are the primary reason that individuals with sickle cell disease are admitted to the hospital. These acute painful episodes are unpredictable and can have devastating effects on the patient’s health.

However, the first targeted therapy for sickle cell disease and associated vaso-occlusive crises, Adakveo® (crizanlizumab), has received approval for use by the U.S. Food and Drug Administration, a huge step in the direction of treatment and management of sickle cell disease. Monthly, intravenous Adakveo can help reduce frequency of vaso-occlusive crises in adults and pediatric patients ages 16 and older.

Please CLICK HERE to read the complete article on the Alabama NewsCenter website.

Category: ALL POSTS, Partner News Stories

About the Author ()

Comments are closed.